A slew of information is pouring out of the American Society for Clinical Oncology (ASCO) Annual Meeting this week. Now we have results from the Prolaris test, launched in 2010. The test is designed to measure the activity of cell cycle progression (CCP) genes in prostate cancer biopsy samples, and was evaluated for its ability to predict either death from prostate cancer, or a risk in the PSA (biochemical recurrence) in 5 company-sponsored trials. The studies included a multivariate analysis (accounting for variables such as grade and PSA). Overall, the CCP score was a highly significant predictor of outcome in all studies. In other words, the test appears to discriminate who is at high risk for progression of cancer. Exactly how we will use this test is being developed, but it may be especially useful for patients with low-grade, low-risk cancers. The Prolaris test for prostate cancer is predictive of a patient’s response to therapy. Still, we don’t have firm risk cutoffs to steer decisions toward a different treatment. Other tests are emerging, too, including the just-launched Oncotype DX test (Genomics Health). I’m Dr Michael Hunter.
Caveat emptor: This information is general only, and should not be construed as medical advise for an individual. Please check with you valued health care provider to determining optimal management for you.